Epistem Holdings Plc ' Product Pipeline Review ' 2012
Summary
Global Market Direct's pharmaceuticals report, "Epistem Holdings Plc - Product Pipeline Review - 2012" provides data on the Epistem Holdings Plc's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Epistem Holdings Plc's corporate website, SEC filings, investor presentations and featured press releases, both from Epistem Holdings Plc and industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Epistem Holdings Plc - Brief Epistem Holdings Plc overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Epistem Holdings Plc human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of Epistem Holdings Plc with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Epistem Holdings Plc's pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products.
Reasons to buy
- Evaluate Epistem Holdings Plc's strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Epistem Holdings Plc in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Epistem Holdings Plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Epistem Holdings Plc. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Epistem Holdings Plc and identify potential opportunities in those areas.
1. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Epistem Holdings Plc ' Product Pipeline Review ' 2012
Published on December 2012
Report Summary
Epistem Holdings Plc ' Product Pipeline Review ' 2012
Summary
Global Market Direct's pharmaceuticals report, "Epistem Holdings Plc - Product Pipeline Review - 2012" provides data on the Epistem
Holdings Plc's research and development focus. The report includes information on current developmental pipeline, complete with
latest updates, and features on discontinued and dormant projects.
This report is built using data and information sourced from Global Markets Direct's proprietary databases, Epistem Holdings Plc's
corporate website, SEC filings, investor presentations and featured press releases, both from Epistem Holdings Plc and
industry-specific third party sources, put together by Global Markets Direct's team.
Scope
- Epistem Holdings Plc - Brief Epistem Holdings Plc overview including business description, key information and facts, and its
locations and subsidiaries.
- Review of current pipeline of Epistem Holdings Plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,
across the globe.
- Product profiles for late stage and clinical stage products of Epistem Holdings Plc with complete description of the product's
developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Epistem Holdings Plc's pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Epistem Holdings Plc's strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Epistem Holdings Plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Epistem Holdings Plc's R&D portfolio and develop key strategic initiatives to
reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Epistem Holdings Plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Epistem Holdings Plc and identify potential opportunities in those areas.
Epistem Holdings Plc ' Product Pipeline Review ' 2012 (From Slideshare) Page 1/6
2. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Table of Content
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Epistem Holdings Plc Snapshot 5
Epistem Holdings Plc Overview 5
Key Information 5
Key Facts 5
Epistem Holdings Plc ' Research and Development Overview 6
Key Therapeutic Areas 6
Epistem Holdings Plc ' Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products ' Monotherapy 9
Epistem Holdings Plc ' Pipeline Products Glance 10
Epistem Holdings Plc ' Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Epistem Holdings Plc ' Drug Profiles 11
Epi-2221 11
Product Description 11
Mechanism of Action 11
R&D Progress 11
Epi-288 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Epi-3905 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
Epi-6 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
Epistem Holdings Plc ' Pipeline Analysis 15
Epistem Holdings Plc ' Pipeline Products by Therapeutic Class 15
Epistem Holdings Plc ' Company Statement 16
Epistem Holdings Plc ' Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Financial Deals Landscape 19
Epistem Holdings Plc, Deals Summary 19
Epistem Holdings Plc, Pharmaceuticals & Healthcare, Deal Details 20
Partnerships 20
Epistem Holdings Plc ' Product Pipeline Review ' 2012 (From Slideshare) Page 2/6
3. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 20
Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 21
Epistem Holdings Enters Into Co-Marketing Agreement With Xcelris Labs For Molecular Tuberculosis Diagnostic Test 22
EpiStem Enters Into Research And Development Agreement With Novartis 23
Kyowa Hakko Kirin Enters Into Co-Development Agreement With Epistem 25
Equity Offering 26
Epistem Announces Private Placement Of Shares For $7 Million 26
Epistem Holdings Completes Private Placement Of Common Stock For $4.3 Million 28
Epistem Raises $5 Million In Private Financing 30
Epistem Holdings Completes Private Placement Of $2 Million 32
Epistem Holdings Completes IPO For $6.12 Million 34
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37
List of Tables
Epistem Holdings Plc, Key Information 5
Epistem Holdings Plc, Key Facts 5
Epistem Holdings Plc ' Pipeline by Indication, 2012 7
Epistem Holdings Plc ' Pipeline by Stage of Development, 2012 8
Epistem Holdings Plc ' Monotherapy Products in Pipeline, 2012 9
Epistem Holdings Plc ' Pre-Clinical, 2012 10
Epistem Holdings Plc ' Pipeline By Therapeutic Class, 2012 15
Epistem Holdings Plc, Subsidiaries 18
Epistem Holdings Plc, Deals Summary 19
Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 20
Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 21
Epistem Holdings Enters Into Co-Marketing Agreement With Xcelris Labs For Molecular Tuberculosis Diagnostic Test 22
EpiStem Enters Into Research And Development Agreement With Novartis 23
Kyowa Hakko Kirin Enters Into Co-Development Agreement With Epistem 25
Epistem Announces Private Placement Of Shares For $7 Million 26
Epistem Holdings Completes Private Placement Of Common Stock For $4.3 Million 28
Epistem Raises $5 Million In Private Financing 30
Epistem Holdings Completes Private Placement Of $2 Million 32
Epistem Holdings Completes IPO For $6.12 Million 34
List of Figures
Epistem Holdings Plc ' Product Pipeline Review ' 2012 (From Slideshare) Page 3/6
4. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Epistem Holdings Plc ' Pipeline by Indication, 2012 7
Epistem Holdings Plc ' Pipeline by Stage of Development, 2012 8
Epistem Holdings Plc ' Monotherapy Products in Pipeline, 2012 9
Epistem Holdings Plc ' Pipeline By Therapeutic Class, 2012 15
Epistem Holdings Plc ' Product Pipeline Review ' 2012 (From Slideshare) Page 4/6
5. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact
Order Information
Please verify that the product information is correct and select the format(s) you require.
Epistem Holdings Plc ' Product Pipeline Review ' 2012
Product Formats
Please select the product formats and the quantity you require.
1 User License--USD 1 500.00 Quantity: _____
Site License--USD 3 000.00 Quantity: _____
Corporate License--USD 4 500.00 Quantity: _____
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title: Mr Mrs Dr Miss Ms Prof
First Name: _____________________________ Last Name: __________________________________
Email Address: __________________________________________________________________________
Job Title: __________________________________________________________________________
Organization: __________________________________________________________________________
Address: __________________________________________________________________________
City: __________________________________________________________________________
Postal / Zip Code: __________________________________________________________________________
Country: __________________________________________________________________________
Phone Number: __________________________________________________________________________
Fax Number: __________________________________________________________________________
Epistem Holdings Plc ' Product Pipeline Review ' 2012 (From Slideshare) Page 5/6
6. Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!
Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.
Payment by credit card Card Number: ______________________________________________
Expiry Date __________ / _________
CVV Number _____________________
Card Type (ex: Visa, Amex…) _________________________________
Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189
Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE
Customer signature:
Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms
Please fax this form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
Epistem Holdings Plc ' Product Pipeline Review ' 2012 (From Slideshare) Page 6/6